DOP2014000178A - Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 - Google Patents
Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2Info
- Publication number
- DOP2014000178A DOP2014000178A DO2014000178A DO2014000178A DOP2014000178A DO P2014000178 A DOP2014000178 A DO P2014000178A DO 2014000178 A DO2014000178 A DO 2014000178A DO 2014000178 A DO2014000178 A DO 2014000178A DO P2014000178 A DOP2014000178 A DO P2014000178A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- mogat
- bencil
- inhibitors
- new
- derivatives useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592717P | 2012-01-31 | 2012-01-31 | |
| EP12382432 | 2012-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2014000178A true DOP2014000178A (es) | 2014-08-31 |
Family
ID=47148691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2014000178A DOP2014000178A (es) | 2012-01-31 | 2014-07-30 | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8575352B2 (enExample) |
| EP (1) | EP2809651B1 (enExample) |
| JP (1) | JP2015511232A (enExample) |
| KR (1) | KR20140106750A (enExample) |
| CN (1) | CN104066719B (enExample) |
| AP (1) | AP2014007794A0 (enExample) |
| AR (1) | AR089771A1 (enExample) |
| AU (1) | AU2013215468A1 (enExample) |
| BR (1) | BR112014018636A8 (enExample) |
| CA (1) | CA2859995A1 (enExample) |
| CL (1) | CL2014001861A1 (enExample) |
| CO (1) | CO7010839A2 (enExample) |
| CR (1) | CR20140322A (enExample) |
| DO (1) | DOP2014000178A (enExample) |
| EA (1) | EA201491276A1 (enExample) |
| ES (1) | ES2590929T3 (enExample) |
| GT (1) | GT201400167A (enExample) |
| HK (1) | HK1199025A1 (enExample) |
| IL (1) | IL233712A0 (enExample) |
| MA (1) | MA35886B1 (enExample) |
| MX (1) | MX2014008599A (enExample) |
| PE (1) | PE20141679A1 (enExample) |
| PH (1) | PH12014501711A1 (enExample) |
| SG (1) | SG11201404106QA (enExample) |
| TW (1) | TW201343629A (enExample) |
| WO (1) | WO2013116075A1 (enExample) |
| ZA (1) | ZA201404836B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| JP5852269B2 (ja) | 2012-01-31 | 2016-02-03 | イーライ リリー アンド カンパニー | Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体 |
| WO2014074365A1 (en) | 2012-11-06 | 2014-05-15 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
| CA2986611C (en) | 2015-06-15 | 2023-10-03 | Nmd Pharma Aps | Compounds for use in treating neuromuscular disorders |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| JP7608166B2 (ja) | 2019-01-11 | 2025-01-06 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EP1655283A1 (en) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| KR20070085957A (ko) * | 2004-11-10 | 2007-08-27 | 화이자 인코포레이티드 | 치환된 ｎ-설폰일아미노벤질-2-페녹시 아세트아마이드화합물 |
| KR20090051778A (ko) * | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| EP2078719A4 (en) * | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
| KR20090064478A (ko) * | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20110275647A1 (en) | 2009-02-23 | 2011-11-10 | Msd K.K. | Pyrimidin-4-(3h)-one derivatives |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| JP5852269B2 (ja) | 2012-01-31 | 2016-02-03 | イーライ リリー アンド カンパニー | Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体 |
-
2013
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/en not_active Ceased
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Ceased
- 2013-01-24 HK HK14112466.4A patent/HK1199025A1/xx unknown
- 2013-01-24 CA CA2859995A patent/CA2859995A1/en not_active Abandoned
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/en active Active
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201491276A1 (ru) | 2014-10-30 |
| ES2590929T3 (es) | 2016-11-24 |
| EP2809651B1 (en) | 2016-06-29 |
| ZA201404836B (en) | 2017-08-30 |
| IL233712A0 (en) | 2014-09-30 |
| JP2015511232A (ja) | 2015-04-16 |
| CA2859995A1 (en) | 2013-08-08 |
| PE20141679A1 (es) | 2014-11-08 |
| HK1199025A1 (en) | 2015-06-19 |
| BR112014018636A2 (enExample) | 2017-06-20 |
| CL2014001861A1 (es) | 2014-11-07 |
| BR112014018636A8 (pt) | 2017-07-11 |
| AU2013215468A1 (en) | 2014-07-10 |
| WO2013116075A1 (en) | 2013-08-08 |
| CN104066719A (zh) | 2014-09-24 |
| AR089771A1 (es) | 2014-09-17 |
| US20130197039A1 (en) | 2013-08-01 |
| MX2014008599A (es) | 2014-08-22 |
| AP2014007794A0 (en) | 2014-07-31 |
| KR20140106750A (ko) | 2014-09-03 |
| PH12014501711A1 (en) | 2014-10-13 |
| CR20140322A (es) | 2014-08-25 |
| SG11201404106QA (en) | 2014-08-28 |
| CO7010839A2 (es) | 2014-07-31 |
| US8575352B2 (en) | 2013-11-05 |
| GT201400167A (es) | 2015-05-28 |
| TW201343629A (zh) | 2013-11-01 |
| CN104066719B (zh) | 2016-08-24 |
| MA35886B1 (fr) | 2014-12-01 |
| EP2809651A1 (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| CO2018012171A2 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| JO3807B1 (ar) | مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
| MX380092B (es) | Tratamiento de la osteoartritis. | |
| EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
| MX2018010177A (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida. | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ |